Published in Exp Neurol on November 28, 2012
Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology (2014) 2.15
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology (2015) 1.21
Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology (2014) 1.19
Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther (2014) 1.09
c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum Mol Genet (2014) 1.03
Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. Front Mol Neurosci (2014) 1.03
Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry. Sci Rep (2014) 0.95
TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathol (2013) 0.95
Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease. Parkinsonism Relat Disord (2014) 0.88
Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? J Parkinsons Dis (2016) 0.87
Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease. Alzheimers Res Ther (2014) 0.86
Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects. Neurosci Lett (2014) 0.86
Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathol Commun (2015) 0.84
Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. Int J Mol Sci (2016) 0.84
Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease. Front Neurosci (2015) 0.84
The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease. Hum Mol Genet (2014) 0.83
Association of CD33 polymorphism rs3865444 with Alzheimer's disease pathology and CD33 expression in human cerebral cortex. Neurobiol Aging (2014) 0.80
Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy Findings. Mov Disord (2016) 0.79
Sensitive western blotting for detection of endogenous Ser129-phosphorylated α-synuclein in intracellular and extracellular spaces. Sci Rep (2015) 0.78
Expression of suppressor of cytokine signaling genes in human elderly and Alzheimer's disease brains and human microglia. Neuroscience (2014) 0.76
Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity. Acta Neuropathol Commun (2017) 0.75
Multicenter Assessment of Immunohistochemical Methods for Pathological Alpha-Synuclein in Sigmoid Colon of Autopsied Parkinson's Disease and Control Subjects. J Parkinsons Dis (2016) 0.75
Cortical phosphorylated α-Synuclein levels correlate with brain wave spectra in Parkinson's disease. Mov Disord (2016) 0.75
Feasibility Study: Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases. J Neuropathol Exp Neurol (2015) 0.75
Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. F1000Res (2017) 0.75
GBA mutations in Parkinson disease: earlier death but similar neuropathological features. Eur J Neurol (2017) 0.75
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology (1991) 23.01
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol (2002) 6.64
Parkinson's disease. Lancet (2009) 6.60
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank (2008) 4.13
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem (2006) 4.06
α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol (2010) 2.93
Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol (2010) 2.73
Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (2009) 2.67
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest (2002) 2.47
Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol (2002) 2.37
Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J Biol Chem (2003) 2.26
Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci (2008) 2.20
Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci (2001) 2.16
Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem (2008) 1.94
Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res (2006) 1.91
Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Exp Neurol (2007) 1.89
Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol (2008) 1.87
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81
The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol (2010) 1.80
Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem (2002) 1.71
Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci (2011) 1.66
Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci (2009) 1.66
Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol (2003) 1.59
Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem (2009) 1.57
Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol (2000) 1.50
Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration. J Neurosci (2010) 1.49
Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem (2003) 1.47
Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci (2010) 1.46
The N-terminus of the intrinsically disordered protein α-synuclein triggers membrane binding and helix folding. Biophys J (2010) 1.39
Formation and development of Lewy pathology: a critical update. J Neurol (2009) 1.37
Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest (2009) 1.35
Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med (2012) 1.29
Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci (2002) 1.23
Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model. J Neurosci (2011) 1.20
Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol (2009) 1.17
Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J Neural Transm Suppl (2006) 1.09
Cross-seeding effects of amyloid β-protein and α-synuclein. J Neurochem (2012) 1.08
Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J Biol Chem (2010) 1.07
Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death. J Biol Chem (2008) 1.07
Membrane Permeabilization by Oligomeric α-Synuclein: In Search of the Mechanism. PLoS One (2010) 1.05
Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease. Acta Neuropathol (2011) 1.03
Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol (2012) 1.01
Characterization of kinases involved in the phosphorylation of aggregated α-synuclein. J Neurosci Res (2010) 1.00
Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol (2004) 0.98
Oligomeric alpha-synuclein and its role in neuronal death. IUBMB Life (2010) 0.94
Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. Acta Neuropathol (2006) 0.92
Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J Neuropathol Exp Neurol (2006) 0.92
Membrane-bound structure and energetics of alpha-synuclein. Proteins (2008) 0.91
α-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience (2011) 0.89
Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo. Neuroscience (2012) 0.86
Patterns of protein nitration in dementia with Lewy bodies and striatonigral degeneration. Acta Neuropathol (2002) 0.86
Simplified neuropathological diagnosis of dementia with Lewy bodies. Neuropathol Appl Neurobiol (1998) 0.85
Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease. Curr Protein Pept Sci (2010) 0.83
The role of phosphorylation in synucleinopathies: focus on Parkinson's disease. CNS Neurol Disord Drug Targets (2010) 0.83
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun (2006) 10.69
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat Genet (2010) 6.81
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science (2004) 4.81
Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet (2006) 4.80
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med (2009) 4.45
The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank (2008) 4.13
Defining mild cognitive impairment in Parkinson's disease. Mov Disord (2007) 3.92
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 3.36
Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol (2008) 3.13
Case series of painful legs and moving toes: clinical and electrophysiologic observations. Mov Disord (2008) 3.04
Prion-like spreading of pathological α-synuclein in brain. Brain (2013) 2.92
Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol (2010) 2.73
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (2009) 2.67
Sox9 is required for determination of the chondrogenic cell lineage in the cranial neural crest. Proc Natl Acad Sci U S A (2003) 2.64
Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A (2008) 2.59
Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol (2008) 2.58
Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol (2003) 2.36
Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol (2013) 2.29
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
Uncoupling Sonic hedgehog control of pattern and expansion of the developing limb bud. Dev Cell (2008) 2.25
TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain (2007) 2.25
Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet (2009) 2.23
Essential tremor is not associated with cerebellar Purkinje cell loss. Mov Disord (2014) 2.17
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med (2008) 2.10
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J (2004) 2.08
Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol (2008) 2.04
Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol (2009) 2.01
Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol (2005) 1.98
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol (2006) 1.94
TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol (2014) 1.90
Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Exp Neurol (2007) 1.89
Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord (2009) 1.89
Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics (2006) 1.88
Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol (2008) 1.81
Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med (2003) 1.79
Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord (2008) 1.78
Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol (2013) 1.77
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement (2013) 1.77
Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett (2008) 1.76
Alzheimer's disease a century later. J Clin Psychiatry (2006) 1.74
Relationship of cognitive measures and gray and white matter in Alzheimer's disease. J Alzheimers Dis (2006) 1.74
Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol (2006) 1.73
C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology (2013) 1.70
Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol (2010) 1.69
Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol (2006) 1.64
The effects of familiarization on intelligibility and lexical segmentation in hypokinetic and ataxic dysarthria. J Acoust Soc Am (2002) 1.64
Brain biochemistry in autopsied patients with essential tremor. Mov Disord (2011) 1.56